NCT01887938View on ClinicalTrials.gov

An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 23, 2013

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Metachromatic Leukodystrophy (MLD)
Interventions
BIOLOGICAL

HGT-1110

Participants will receive IT injection of HGT-1110.

Trial Locations (15)

2100

Rigshospitalet, Copenhagen

2145

The Children's Hospital at Westmead, Westmead

26133

Klinikum Oldenburg, Oldenburg

34000

Hopital Gui de Chauliac - CHRU de Montpellier, Montpellier

44093

CHU de Nantes, Nantes

45067

CHR Orleans - Hopital La Source, Orléans

46483

Marien-Hospital Wesel gGmbh, Wesel

61300

Detska Interni Klinika, Lf Mu A Fn Brno, Brno

72076

Center for Pediatric Clinical Studies (CPCS), Tübingen

94275

Hôpital de Bicêtre, Le Kremlin-Bicêtre

90035-003

Hospital de Clinicas de Porto Alegre, Porto Alegre

69 677

Hopital Femme Mere Enfant, Bron

805-8534

Kitakyushu Municipal Yahata Hospital, Fukuoka

710-8602

Kurashiki Central Hospital, Okayama Prefecture

565-0871

Osaka University Hospital, Osaka

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Shire

INDUSTRY

NCT01887938 - An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy | Biotech Hunter | Biotech Hunter